Page last updated: 2024-12-06

5,6-dihydroxy-2-dimethylaminotetralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,6-dihydroxy-2-dimethylaminotetralin, also known as 2-DMAT, is a synthetic dopamine agonist that has been studied for its potential therapeutic effects in Parkinson's disease and other neurological disorders. It acts as a partial agonist at dopamine receptors, mimicking the effects of dopamine but with lower efficacy. 2-DMAT has been shown to improve motor function and reduce symptoms in animal models of Parkinson's disease. However, its clinical use has been limited due to its short half-life and potential side effects, such as nausea and vomiting. 2-DMAT is synthesized through a multi-step process involving the condensation of 2-aminotetralin with formaldehyde followed by oxidation with potassium permanganate. Its importance lies in its ability to provide insights into the role of dopamine in the brain and its potential for the development of new therapies for neurological disorders.'

5,6-dihydroxy-2-dimethylaminotetralin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID37033
CHEMBL ID146419
CHEBI ID125443
SCHEMBL ID6286848
MeSH IDM0055083

Synonyms (22)

Synonym
m 7 (pharmaceutical)
CHEBI:125443
CHEMBL146419 ,
6-(dimethylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol
n,n-dimethyl-5,6-dihydroxy-2-aminotetralin
2-n,n-dimethylamino-5,6-dihydroxytetralin
1,2-naphthalenediol, 6-(dimethylamino)-5,6,7,8-tetrahydro-
m-7
5,6-dihydroxy-2-dimethylaminotetralin
39478-90-5
2-(dimethylamino)-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene
n,n-dimethyl-5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene
6-(dimethylamino)-5,6,7,8-tetrahydro-1,2-naphthalenediol
BRD-A77864279-001-01-6
SCHEMBL6286848
Q27216060
5,6-dihydroxy-2-dimethylamino tetralin
DTXSID40929140
135743-24-7
bdbm50225290
1,2-naphthalenediol,6-(dimethylamino)-5,6,7,8-tetrahydro-(9ci)
AKOS040749974

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5 micrograms/kg per min) that was continued while dose-response curves to M-7 and cirazoline were generated."( Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil.
Cavero, I; Langer, SZ; Lefèvre-Borg, F; Shepperson, N, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tetralinsCompounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1144411Inhibition of prolactin secretion in rat assessed as serum prolactin level at 1 ug, ip after 1 hr by radioimmunoassay relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Ergoline congeners as potential inhibitors of prolactin release. 2.
AID63119Evaluated for the percentage vasodilation in the renal artery produced by 3000 nmol administered intra-arterially; NA is No Antagonistic activity1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists.
AID3678350% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID36715Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID197169Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (84.00)18.7374
1990's1 (4.00)18.2507
2000's0 (0.00)29.6817
2010's1 (4.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]